Vertex advances vx-147 into pivotal clinical development for people with apol1-mediated kidney disease

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the company has advanced vx-147 into pivotal development for people living with proteinuric kidney disease mediated by two mutations in the apol1 gene (amkd), which affects approximately 100,000 people in the u.s. and europe. vx-147 is the first investigational therapy aimed at treating the underlying cause of amkd. the pivotal study will open for enrollment later this month. the company will evalua
VRTX Ratings Summary
VRTX Quant Ranking